Biopharma industry trade publication Endpoints News cited William Blair’s Quarterly Rx, a report from the firm’s investment banking team focused on M&A and equity capital market activity in the biopharma sector, in a 2025 M&A outlook story.
“The firm’s bankers predict 2025 will have ‘meaningful public company M&A’ and about 30 IPOs,” the report that was cited by the publication noted.